Enhancing the presentation of tumor antigens has been proposed as a viable therapy option, and peptide-based glioma vaccine was successfully developed to activate the MHC class II molecules-dependent CD4+ T cells [14]. This evidence concerns the gene CD4 and central nervous system cancer.